All In MedTech

FDA Clearance Tracker · P110022-S027

Elecsys Anti-HBc IgM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P110022-S027
Device name
Elecsys Anti-HBc IgM
Applicant location
Indianapolis, IN
Received
Oct 26, 2018
Decided
Apr 24, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P110022

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site for the cobas e 411 Analyzer located at Hitachi High-Technologies Corp., 1892-1, Oazategama, Omuta, Fukuoka, 836-0004 Japan

Source documents

Other decisions for Roche Diagnostics Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.